Vaccine formulation, pharmaceutical formulation, attenuated influenza virus, processes to vaccinate an individual, to prevent an infectious disease in an individual, and, to treat or prevent tumors in an individual

摘要

"VACCINE FORMULATION, PHARMACEUTICAL FORMULATION, ATTENUATED INFLUENCE VIRUS, PROCESSES TO VACCINE AN INDIVIDUAL, TO PREVENT AN INFECTIOUS DISEASE IN AN INDIVIDUAL, AND, TO TREAT OR PREVENT TUMORS IN AN INDIVIDUAL." The present invention generally relates to attenuated, negative-stranded RNA viruses, having an impaired ability to antagonize the response to cellular interferon (IFN), and the use of these attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of systems deficient in IFN for selection of these attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that decrease or eliminate the ability of the NS1 gene product to antagonize the response to cellular IFN. Mutant viruses replicate in vivo but demonstrate reduced pathogenicity and are thus well suited for virus vaccines and pharmaceutical formulations.